Literature DB >> 21411717

Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis.

Gunnar Tomasson1, Michael Lavalley, Kahraman Tanriverdi, Javier D Finkielman, John C Davis, Gary S Hoffman, W Joseph McCune, E William St Clair, Ulrich Specks, Robert Spiera, John H Stone, Jane E Freedman, Peter A Merkel.   

Abstract

OBJECTIVE: There remains a need for biomarkers to guide therapy in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Our objective was to determine whether measures of platelet activation or inflammation are associated with disease activity in Wegener's granulomatosis (WG).
METHODS: Study subjects were participants in a clinical trial. Soluble CD40 ligand (sCD40L), C-reactive protein, interleukin 6 (IL-6), IL-8, monocyte chemoattractant protein 1 (MCP-1), P-selectin, vascular endothelial growth factor, and proteinase 3 (PR3)-specific ANCA were measured by ELISA using plasma samples obtained at baseline (active disease), at remission, and prior to, during, and after first flares. Disease activity was assessed by the Birmingham Vasculitis Activity Score for WG (BVAS/WG). Association of biomarkers with disease activity was determined with conditional logistic and linear regression.
RESULTS: Over a mean followup of 27 months, 180 subjects underwent 2044 visits; markers were measured in 563 samples. Longitudinally, all markers other than IL-6 were associated with disease activity. The strongest associations for active disease at baseline versus remission were observed for sCD40L (OR 4.72, 95% CI 2.47-9.03), P-selectin (OR 6.26, 95% CI 2.78-14.10), PR3-ANCA (OR 9.41, 4.03-21.99), and inversely for MCP-1 (OR 0.36, 95% CI 0.22-0.57). BVAS/WG increased by 0.80 (95% CI 0.44-1.16), 0.83 (95% CI 0.42-1.25), and 0.81 (95% CI 0.48-1.15) per unit-increase in PR3-ANCA, sCD40L, and P-selectin, respectively; and decreased by 1.54 (95% CI 0.96-2.12) per unit-increase in MCP-1.
CONCLUSION: Cytokines arising from within the circulation, including those of platelet activation, correlate with disease activity in WG.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21411717      PMCID: PMC3653633          DOI: 10.3899/jrheum.100735

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  38 in total

1.  Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study.

Authors:  T Girard; A Mahr; L H Noël; J F Cordier; P Lesavre; M H André; L Guillevin
Journal:  Rheumatology (Oxford)       Date:  2001-02       Impact factor: 7.580

2.  A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

Authors:  J H Stone; G S Hoffman; P A Merkel; Y I Min; M L Uhlfelder; D B Hellmann; U Specks; N B Allen; J C Davis; R F Spiera; L H Calabrese; F M Wigley; N Maiden; R M Valente; J L Niles; K H Fye; J W McCune; E W St Clair; R A Luqmani
Journal:  Arthritis Rheum       Date:  2001-04

3.  Serum levels of soluble adhesion molecules ICAM-1, VCAM-1 and E-selectin in patients with Wegener's granulomatosis.

Authors:  N Ohta; S Fukase; M Aoyagi
Journal:  Auris Nasus Larynx       Date:  2001-11       Impact factor: 1.863

4.  Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells.

Authors:  Tae-Hee Lee; Hava Avraham; Seung-Hoon Lee; Shalom Avraham
Journal:  J Biol Chem       Date:  2002-01-09       Impact factor: 5.157

5.  The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40.

Authors:  V Henn; S Steinbach; K Büchner; P Presek; R A Kroczek
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

6.  Recurrent venous thrombosis and markers of inflammation.

Authors:  B E van Aken; M den Heijer; G M Bos; S J van Deventer; P H Reitsma
Journal:  Thromb Haemost       Date:  2000-04       Impact factor: 5.249

7.  Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions.

Authors:  Kimberly A Russell; Elaine Wiegert; Darrell R Schroeder; Henry A Homburger; Ulrich Specks
Journal:  Clin Immunol       Date:  2002-05       Impact factor: 3.969

8.  Inflammatory response in the acute phase of deep vein thrombosis.

Authors:  Edith M Roumen-Klappe; Martin den Heijer; Stan H M van Uum; Johanna van der Ven-Jongekrijg; Fedde van der Graaf; Hub Wollersheim
Journal:  J Vasc Surg       Date:  2002-04       Impact factor: 4.268

9.  Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients.

Authors:  Abdolreza Rezaie-Majd; Thomas Maca; Robert A Bucek; Peter Valent; Michael R Müller; Peter Husslein; Ahmad Kashanipour; Erich Minar; Mehrdad Baghestanian
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-07-01       Impact factor: 8.311

10.  Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.

Authors:  Christian Pagnoux; Susan L Hogan; Hyunsook Chin; J Charles Jennette; Ronald J Falk; Loïc Guillevin; Patrick H Nachman
Journal:  Arthritis Rheum       Date:  2008-09
View more
  22 in total

Review 1.  Innate immune cells in the pathogenesis of primary systemic vasculitis.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2015-09-24       Impact factor: 2.631

Review 2.  Biomarkers in ANCA-associated vasculitis.

Authors:  Lindsay Lally; Robert F Spiera
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

3.  High serum hepcidin is associated with the occurrence of anemia in anti-myeloperoxidase antibody-associated vasculitis with normal kidney function: a cross-sectional study.

Authors:  Tong Chen; Peng-Cheng Xu; Shui-Yi Hu; Shan Gao; Jun-Ya Jia; Tie-Kun Yan
Journal:  Rheumatol Int       Date:  2019-03-29       Impact factor: 2.631

Review 4.  Endothelium-neutrophil interactions in ANCA-associated diseases.

Authors:  Lise Halbwachs; Philippe Lesavre
Journal:  J Am Soc Nephrol       Date:  2012-09       Impact factor: 10.121

5.  Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.

Authors:  Paul A Monach; Roscoe L Warner; Gunnar Tomasson; Ulrich Specks; John H Stone; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Iklé; Cees G M Kallenberg; Jeffrey Krischer; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Kent J Johnson; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2012-09-12       Impact factor: 19.103

6.  urinary biomarkers in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Jason G Lieberthal; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Kathleen Maksimowicz-McKinnon; Philip Seo; Ulrich Specks; Steven R Ytterberg; Peter A Merkel; Paul A Monach
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

7.  Circulating ADAM17 Level Reflects Disease Activity in Proteinase-3 ANCA-Associated Vasculitis.

Authors:  Anna Bertram; Svjetlana Lovric; Alissa Engel; Michaela Beese; Kristin Wyss; Barbara Hertel; Joon-Keun Park; Jan U Becker; Johanna Kegel; Hermann Haller; Marion Haubitz; Torsten Kirsch
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

8.  Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis.

Authors:  Alicia Rodriguez-Pla; Roscoe L Warner; David Cuthbertson; Simon Carette; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Steven R Ytterberg; Kent J Johnson; Peter A Merkel; Paul A Monach
Journal:  J Rheumatol       Date:  2019-09-01       Impact factor: 4.666

9.  Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab.

Authors:  Donna O'Dell Bunch; JulieAnne G McGregor; Nirmal B Khandoobhai; Lydia T Aybar; Madelyn E Burkart; Yichun Hu; Susan L Hogan; Caroline J Poulton; Elisabeth A Berg; Ronald J Falk; Patrick H Nachman
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-04       Impact factor: 8.237

Review 10.  Biomarkers in vasculitis.

Authors:  Paul A Monach
Journal:  Curr Opin Rheumatol       Date:  2014-01       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.